Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Lichterfeld M, Nischalke HD, Bergmann F, Wiesel W, Rieke A, Theisen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H, Wasmuth JC, Rockstroh JK. Lichterfeld M, et al. Among authors: fatkenheuer g. HIV Med. 2002 Jan;3(1):37-43. doi: 10.1046/j.1464-2662.2001.00091.x. HIV Med. 2002. PMID: 12059949 Free article. Clinical Trial.
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H. Rockstroh JK, et al. Among authors: fatkenheuer g. AIDS. 2000 Jun 16;14(9):1181-5. doi: 10.1097/00002030-200006160-00015. AIDS. 2000. PMID: 10894282 Clinical Trial.
PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.
Fätkenheuer G, Jessen H, Stoehr A, Jung N, Jessen AB, Kümmerle T, Berger M, Bogner JR, Spinner CD, Stephan C, Degen O, Vogelmann R, Spornraft-Ragaller P, Schnaitmann E, Jensen B, Ulmer A, Kittner JM, Härter G, Malfertheiner P, Rockstroh J, Knecht G, Scholten S, Harrer T, Kern WV, Salzberger B, Schürmann D, Ranneberg B. Fätkenheuer G, et al. HIV Med. 2016 Jun;17(6):453-9. doi: 10.1111/hiv.12363. Epub 2016 May 11. HIV Med. 2016. PMID: 27166295 Free article. Clinical Trial.
Predictors of serofast state after treatment for early syphilis in HIV-infected patients.
Paul G, Wesselmann J, Adzic D, Malin JJ, Suarez I, Priesner V, Kümmerle T, Wyen C, Jung N, van Bremen K, Schlabe S, Wasmuth JC, Boesecke C, Fätkenheuer G, Rockstroh J, Schwarze-Zander C, Lehmann C. Paul G, et al. Among authors: fatkenheuer g. HIV Med. 2021 Mar;22(3):165-171. doi: 10.1111/hiv.12985. Epub 2020 Oct 30. HIV Med. 2021. PMID: 33128333 Free article.
HIV DNA reservoir and elevated PD-1 expression of CD4 T-cell subsets particularly persist in the terminal ileum of HIV-positive patients despite cART.
Horn C, Augustin M, Ercanoglu MS, Heger E, Knops E, Bondet V, Duffy D, Chon SH, Nierhoff D, Oette M, Schäfer H, Vivaldi C, Held K, Anderson J, Geldmacher C, Suárez I, Rybniker J, Klein F, Fätkenheuer G, Müller-Trutwin M, Lehmann C. Horn C, et al. Among authors: fatkenheuer g. HIV Med. 2021 May;22(5):397-408. doi: 10.1111/hiv.13031. Epub 2021 Jan 9. HIV Med. 2021. PMID: 33421299 Free article.
548 results